This trial will compare the effects of a study drug on bile acids, measure how much gets into the bloodstream, and check safety/tolerability in people with normal/impaired kidney function.
- Chronic Hepatitis D
- Chronic Hepatitis Delta Infection
2 Primary · 12 Secondary · Reporting Duration: Day 1: Predose up to 24 hours postdose and Day 6: Predose up to 48 hours postdose
Awards & Highlights
2 Treatment Groups
Group A: Bulevirtide (BLV), Severe Renal Impaired Participants
1 of 2
Group A: BLV, Normal Renal Function (Matched Control Participants)
1 of 2
80 Total Participants · 2 Treatment Groups
Primary Treatment: Group A: Bulevirtide (BLV), Severe Renal Impaired Participants · No Placebo Group · Phase 1
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Age 18 - 79 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Could I potentially join this clinical experiment?
"Eligibility for this trial requires that candidates are between 18 and 79 years old, as well as have a chronic hepatitis d diagnosis. Currently, 80 individuals are being recruited to partake in the study." - Anonymous Online Contributor
Are participants who are youthful than 70 years old qualified to participate in this trial?
"To be eligible for this research, participants must fulfill the age criteria of 18 to 79 years. There are 6 trials that cater exclusively to those under 18 and 168 specifically designed for patients over 65." - Anonymous Online Contributor
Is there any vacancy for participants in the trial?
"The evidence accessible on clinicaltrials.gov suggests that this medical trial is no longer recruiting patients, although it was initially posted on March 1st 2023 and edited for the last time 24 days later. However, at present there are 175 other studies actively looking for volunteers to participate in them." - Anonymous Online Contributor
Is Group A: BLV, Normal Renal Function (Matched Control Participants) safe for human consumption?
"Our team at Power analyses the safety of Group A: BLV, Normal Renal Function (Matched Control Participants) to be a 1 due to its phase 1 status. This is because there is limited data on both efficacy and safety." - Anonymous Online Contributor